RxDoctor Payments Data

Roberto Calderon Santiago

Internal Medicine · San Juan, PRNPI 1851460166

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $13,440 of the $20,248 with a category attached, or 66.4%. Merck accounts for 69.7% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $8,660 and has fallen 88.2% since, to $1,023 in 2025. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,248in general payments, 2019–2025

Across 164 payments — averaging $123.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$14K
  • Viiv Healthcare Company$3K
  • Johnson & Johnson$2K
  • Gilead$843
  • Theratechnologies Inc.$589
  • Janssen Products, LP$99
  • plus $216 from 5 others

What the payments were for

  • Speaking & faculty fees$13,44066%
  • Food & beverage$6,62633%
  • Education$1821%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,248 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Most prescribed under Part D

DrugClaimsCost to plans & patients
JulucaDolutegravir/Rilpivirine56$358,995
DovatoDolutegravir Sodium/Lamivudine101$343,511
TriumeqAbacavir/Dolutegravir/Lamivudi57$243,589
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf32$188,328
BiktarvyBictegrav/Emtricit/Tenofov Ala23$163,224
PrezcobixDarunavir/Cobicistat31$105,370
OdefseyEmtricitab/Rilpiviri/Tenof Ala17$89,239
Egrifta SvTesamorelin Acetate12$85,958
TivicayDolutegravir Sodium22$65,111
Isentress HdRaltegravir Potassium20$50,919
DelstrigoDoravirine/Lamivu/Tenofov Diso15$40,984
IsentressRaltegravir Potassium11$29,959
DescovyEmtricitabine/Tenofov Alafenam11$23,981
FarxigaDapagliflozin Propanediol14$17,368
XareltoRivaroxaban15$12,994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyJuluca, Dovato, Triumeq, Tivicay$2,668$1,011,206236 claims
Janssen Products, LPSymtuza$99$188,32832 claims
GileadBiktarvy, Descovy$843$187,20534 claims
MerckIsentress Hd, Delstrigo, Isentress$14,115$121,86246 claims
Johnson & JohnsonPrezcobix, Xarelto$1,717$118,36446 claims
Theratechnologies Inc.Egrifta Sv$589$85,95812 claims
AbbVieSynthroid, Alphagan P$84$7,16654 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →